Literature DB >> 22836385

[Macrophage activation syndrome].

P Lehmann1, E Huber, T Dörner, M Fleck.   

Abstract

Macrophage activation syndrome (MAS) is an infrequent but potentially life-threatening complication of various autoimmune diseases. It is characterized by excessive activation of macrophages induced by a dysfunction of the immune system, although the underlying abnormalities remain to be delineated. Sepsis-like symptoms accompanied by cytopenia, hepatosplenomegaly, coagulopathy and multiple organ dysfunctions are typical disease manifestations. Due to the lack of validated classification criteria and distinct laboratory markers, the diagnosis of MAS is often difficult to establish. However, early diagnosis and therapy is of utmost importance to ensure best possible outcome. Treatment regimens include high doses of glucocorticoids, classical immunosuppressive agents as well as novel biologics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836385     DOI: 10.1007/s00393-012-0987-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  34 in total

Review 1.  Soluble CD163.

Authors:  Holger J Møller
Journal:  Scand J Clin Lab Invest       Date:  2011-11-07       Impact factor: 1.713

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

3.  Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept.

Authors:  Keisuke Maeshima; Koji Ishii; Mikako Iwakura; Misuzu Akamine; Hajime Hamasaki; Itomi Abe; Miwa Haranaka; Hiroshi Tatsukawa; Hironobu Yoshimatsu
Journal:  Mod Rheumatol       Date:  2011-06-14       Impact factor: 3.023

Review 4.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  G E Janka
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

5.  Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome.

Authors:  Masafumi Kobayashi; Yuko Takahashi; Hiroyuki Yamashita; Hiroshi Kaneko; Akio Mimori
Journal:  Mod Rheumatol       Date:  2010-08-26       Impact factor: 3.023

Review 6.  Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Tadamitsu Kishimoto
Journal:  Expert Rev Clin Immunol       Date:  2010-09       Impact factor: 4.473

7.  Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review.

Authors:  Robin Dhote; Jeanne Simon; Thomas Papo; Bruno Detournay; Laurent Sailler; Marie-Helene Andre; Jean-Louis Dupond; Claire Larroche; Anne-Marie Piette; Didier Mechenstock; Jean-Marc Ziza; Jean Arlaud; Anne-Sophie Labussiere; Agnes Desvaux; Vincent Baty; Philippe Blanche; Annette Schaeffer; Jean-Charles Piette; Loïc Guillevin; Alain Boissonnas; Boyan Christoforov
Journal:  Arthritis Rheum       Date:  2003-10-15

8.  A case of macrophage activation syndrome successfully treated with anakinra.

Authors:  Alison Kelly; Athimalaipet V Ramanan
Journal:  Nat Clin Pract Rheumatol       Date:  2008-09-30

9.  The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis.

Authors:  Abha Gupta; Pascal Tyrrell; Rahim Valani; Susanne Benseler; Sheila Weitzman; Mohamed Abdelhaleem
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

Review 10.  Human primary immunodeficiency diseases: a perspective.

Authors:  Alain Fischer
Journal:  Nat Immunol       Date:  2004-01       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.